CiMaas, together with the Maastricht University Medical Center+ and the University Medical Center Utrecht have received a subsidy of € 1,48 million to further develop Natural Killer Cell therapy for breast cancer.

These funds will allow the consortium to further develop their NK cell expansion technology as well as creating Next generation NK cells. These cells will further be tested in human organoid cultures and proper in vivo models.

The subsidy is provided by the Dutch KWF Cancer Research Fundfonds for the national initiative LSH-TKI (Life Science Health, Top Consortia for Knowledge and Innovation) Health-Holland.